The asunaprevir and daclatasvir reports were sent in last week. We now wait to hear the outcome of the submissions. Thank you to all of you who completed PHCN’s Asunaprevir and Daclatasvir Survey and shared it with others. All of the responses made writing the patient group input reports on your behalf, a relatively simple task.
The patient group input reports requested by the Canadian Agency for Drugs and Technologies in Health (CADTH) are an important step towards getting new treatments for hep C more widely available in Canada and BC. They allow patients to have a say in the drug approval process.
The Hepatitis C Treatment Information Project will keep you apprised of any developments and is full of information about asunaprevir and daclatasvir.
Thank you for taking the time to voice your opinion and help advocate for a better tomorrow.